Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2009-015507-52
    Sponsor's Protocol Code Number:CLBH589D2308
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2009-12-21
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2009-015507-52
    A.3Full title of the trial
    Estudio Fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de panobinostat en combinación con bortezomib y dexametasona, en pacientes con mieloma múltiple en recaída
    A.4.1Sponsor's protocol code numberCLBH589D2308
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovartis Farmacéutica S.A.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namepanobinostat
    D.3.2Product code LBH589
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPanobinostat
    D.3.9.1CAS number 404950-80-7
    D.3.9.2Current sponsor codeLBH589
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namepanobinostat
    D.3.2Product code LBH589
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPanobinostat
    D.3.9.1CAS number 404950-80-7
    D.3.9.2Current sponsor codeLBH589
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name VELCADE 3,5 mg, polvo para solución inyectable
    D.2.1.1.2Name of the Marketing Authorisation holderJANSSEN-CILAG INTERNATIONAL N.V
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPIntravenous bolus use (Noncurrent)
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBORTEZOMIB
    D.3.9.3Other descriptive nameBORTEZOMIB
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Fortecortin 0,5 mg Tabletten
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Pharma GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFortecortin
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDexamethasone
    D.3.9.1CAS number 50-02-2
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Fortecortin 2 mg Tabletten
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Pharma GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFortecortin
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDexamethasone
    D.3.9.1CAS number 50-02-2
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Fortecortin 4 mg Tabletten
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Pharma GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFortecortin
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDexamethasone
    D.3.9.1CAS number 50-02-2
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Fortecortin 8 mg Tabletten
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Pharma GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFortecortin
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDexamethasone
    D.3.9.1CAS number 50-02-2
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number8
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 8
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namepanobinostat
    D.3.2Product code LBH589
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPanobinostat
    D.3.9.1CAS number 404950-80-7
    D.3.9.2Current sponsor codeLBH589
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number15
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Mieloma Múltiple (MM), en pacientes en recaída.
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 12.0
    E.1.2Level LLT
    E.1.2Classification code 10028228
    E.1.2Term Multiple myeloma
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Comparar la supervivencia libre de progresión (SLP), en pacientes tratados con PAN en combinación BTZ/Dex frente a pacientes tratados con placebo en combinación con BTZ/Dex.
    E.2.2Secondary objectives of the trial
    Secundarios principales:
    • Comparar la SG (supervivencia global)Otros secundarios:
    • Comparar la TRG (tasa de respuesta global) que consta de RC, RcC y RP
    • Comparar la TRM (tasa de respuesta menor)
    • Comparar el TR (tiempo hasta la respuesta)
    • Comparar el TP (tiempo hasta la progresión)
    • Evaluar la duración de la respuesta (DR; desde la primera RP que ocurra o mejor)
    • Evaluar la seguridad de la terapia de combinación
    • Evaluar la calidad de vida relacionada con la salud y los síntomas del mieloma múltiple
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Titulo: "Estudio complementario de biomarcadores en el estudio Fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de panobinostat en combinación con bortezomib y dexametasona, en pacientes con mieloma múltiple en recaída". Version 00, fecha 23-Sep-2009.
    Objetivos: Correlacionar las características basales moleculares de la célula del tumor con la respuesta. Investigar la RC molecular definida en los criterios del IMWG80 con ASO-PCR, en pacientes con RC.
    E.3Principal inclusion criteria
    1. Los pacientes deben presentar un diagnóstico previo de mieloma múltiple, basado en las definiciones del IMWG 2003. Deberán haber cumplido los tres siguientes criterios:
    a. Inmunoglobulina monoclonal (componente M) con electroforesis y con inmunofijación en suero o en orina total de 24 horas.
    b. Células plasmáticas (clonales) en la médula ósea &#8805; 10% o plasmocitoma confirmado con biopsia
    c. Afectación relacionada de tejidos u órganos (Síntomas de CRAB: anemia, hipercalcemia, lesiones óseas líticas, insuficiencia renal, hiperviscosidad amiloidosis o infecciones recurrentes)
    2. Pacientes con 1 a 3 líneas previas de terapia que precisen retratamiento del mieloma (cf IMWG 2003) para una de las 2 condiciones siguientes:
    a. En recaída, definida por enfermedad que recurrió en un paciente que respondió bajo una terapia previa, que alcanzó una RM o mejor y que no ha progresado con esta terapia ni hasta 60 días de la última dosis de dicha terapia. Los pacientes tratados previamente con BTZ pueden ser elegibles.
    b. En recaída y refractario a una terapia, siempre que cumpla ambas condiciones:
    - paciente que haya recaído tras por lo menos una línea previa
    - y paciente que fue refractario a otra línea (excepto BTZ), no alcanzando una RM o que progresó bajo dicha terapia, o en un plazo de 60 días de su última dosis.
    3. Los pacientes deben presentar enfermedad medible en proteína M en la selección del estudio, definido por al menos una de las siguientes mediciones, según los límites clarificados en las definiciones de la enfermedad del IMWG 2003 (Kyle, et al 2003):
    • Proteína-M en suero &#8805; 1 g/dL (&#8805; 10 g/L)
    • Proteína-M en orina &#8805; 200 mg/24 h
    4. Los pacientes tratados con radioterapia local con o sin exposición concomitante a esteroides para el control del dolor o para el manejo de la compresión de una raíz nerviosa/medular son elegibles. Deberán haber transcurrido dos semanas desde la última fecha de la radioterapia, que se recomienda que sea de un campo limitado. A los pacientes que precisen radioterapia concurrente se les debería posponer la inclusión en el protocolo hasta que la radioterapia finalice y hayan transcurrido 2 semanas desde la fecha de la última terapia.
    5. La edad del paciente ha de ser &#8805; 18 años en el momento de la firma del consentimiento informado.
    6. El paciente ha de presentar un estado funcional (PS) del Grupo de Oncología Cooperativo del Este de &#8804; 2.
    7. El paciente ha de presentar los siguientes valores de laboratorio dentro de las 3 semanas previas al inicio de la medicación del estudio (los análisis de laboratorio pueden repetirse, cuando esté clínicamente indicado, para obtener valores aceptables antes de considerarlo un fallo de selección, pero no han de administrarse terapias de soporte dentro de la semana previa a los análisis de selección para recuentos de plaquetas o recuento de neutrófilos absoluto)
    a. Recuento de neutrófilos absoluto (ANC) &#8805; 1,5 x 109 /L
    b. Recuento de plaquetas &#8805; 100 x 109 /L
    c. Potasio, magnesio, fósforo séricos dentro de los límites de normalidad (DLN) del centro de estudio
    d. Calcio total (corregido para albúmina sérica) o calcio ionizado &#8805; LIN y no mayor a grado 1 de los CTCAE en caso de valor elevado.
    Nota: Pueden administrarse suplementos de potasio, calcio, magnesio y/o fósforo para corregir valores que sean < LIN:
    e. AST/SGOT y ALT/SGPT &#8804; 2,5 x LSN
    f. Bilirrubina sérica total &#8804; 1,5 LSN (o &#8804; 3,0 x LSN, si el paciente padece síndrome de Gilbert)
    g. Niveles de creatinina sérica &#8804; 1,5 x LSN o aclaramiento de creatinina &#8805; 60 ml/min
    8. El paciente ha de proporcionar el consentimiento informado por escrito antes de cualquier procedimiento de selección.
    9. El paciente ha de poder tragar las cápsulas.
    10. El paciente ha de poder cumplir el calendario de visitas del estudio y otros requisitos del protocolo.
    11. Las mujeres físicamente fértiles (WOCBP) deberán presentar una prueba de embarazo en suero negativa dentro de los 7 días previos al inicio del tratamiento del estudio.
    E.4Principal exclusion criteria
    1. Pacientes que hayan progresado bajo todas las líneas previas de terapia antimieloma (refractario primario)
    2. Pacientes que hayan sido refractarios a BTZ previo
    3. Pacientes que han recibido trasplante alogénico de células madre y que presenten enfermedad injerto contra huésped activa o con necesidad de tratamiento inmunosupresor.
    4. Pacientes que muestren intolerancia a bortezomib o a dexametasona o a componentes de estos fármacos o presenten alguna contraindicación a uno o al otro fármaco, siguiendo la información de prescripción localmente aplicable.
    5. Pacientes con neuropatía periférica &#8805; a grado 2 o neuropatía periférica de grado 1 con dolor en la exploración clínica dentro de los 14 días antes de la aleatorización.
    6. Pacientes que recibieron tratamiento previo con inhibidores de la DAC incluyendo panobinostat.
    7. Pacientes que precisen ácido valproico para cualquier condición médica durante el estudio o durante los 5 días previos a la primera administración de panobinostat/tratamiento del estudio.
    8. Pacientes que tomen cualquier terapia antineoplásica concomitantemente (los bifosfonatos están permitidos sólo si se iniciaron antes del comienzo del periodo de selección)
    9. Pacientes con otra enfermedad maligna primaria < 3 años desde la primera dosis del tratamiento del estudio
    10. Pacientes que recibieron:
    a. quimioterapia antimieloma previa o medicación que incluya IMiDs y Dex &#8804; 3 semanas antes de iniciar el estudio.
    b. terapia experimental o inmunoterapia biológica que incluya anticuerpos monoclonales &#8804; 4 semanas antes del inicio del estudio.
    c. terapia de radiación previa &#8804; 4 semanas o radioterapia de campo limitado &#8804; 2 semanas antes del inicio del estudio.
    11. Pacientes que no se hayan recuperado de todas las toxicidades relacionadas con la terapia asociadas con los tratamientos listados anteriormente a < grado 2 de los CTCAE.
    12. Pacientes que hayan sido sometidos a cirugía mayor &#8804; 2 semanas antes del inicio de la medicación del estudio o que no se hayan recuperado de los efectos secundarios de dicha terapia a < grado 2 de los CTCAE.
    13. Pacientes con evidencia de hemorragia interna o de la mucosa
    14. Pacientes con diarrea no resuelta &#8805; grado 2 de los CTCAE
    15. Pacientes con deterioro de la función cardíaca, incluyendo cualquiera de los siguientes:
    a. LVEF < LIN del valor normal del centro, determinado con ECHO o MUGA
    b. uso obligatorio de un marcapasos cardíaco permanente
    c. síndrome congénito de QT prolongado
    d. antecedentes o presencia de taquiarritmias ventriculares
    e. bradicardia en reposo definida como < 50 pulsaciones por minuto
    f. QTcF > 450 mseg en el ECG de selección
    g. bloqueo completo de rama izquierda (LBBB), bloqueo bifascicular
    h. cualquier segmento ST clínicamente significativo y/o anomalías en la onda T
    i. presencia de fibrilación auricular inestable (velocidad de respuesta ventricular > 100 ppm). Los pacientes con fibrilación auricular estable pueden incluirse siempre que no cumplan otros criterios de exclusión cardíacos.
    j. infarto de miocardio o angina de pecho inestable &#8804; 6 meses antes de iniciar la medicación del estudio
    k. insuficiencia cardíaca congestiva sintomática (clase III-IV de la Asociación de cardiología de Nueva York)
    l. otra enfermedad cardíaca clínicamente significativa o enfermedad vascular (por ejemplo, hipertensión incontrolada)
    16. Pacientes que tomen medicaciones con riesgo relativo de prolongación del intervalo QT o que induzcan Torsade de pointes, si dicho tratamiento no puede ser suspendido o cambiado por otra medicación distinta antes de iniciar la medicación del estudio
    17. Pacientes con deterioro de la función gastrointestinal (GI) o enfermedad GI que pueda alterar significativamente la absorción de panobinostat (por ejemplo, enfermedad ulcerosa, náuseas incontroladas, vómitos, síndrome de mala absorción, obstrucción o resección del intestino delgado y/o estómago)
    18. Pacientes con cualquier otra condición médica incontrolada y/o severa concurrente (por ejemplo, diabetes incontrolada, infección incontrolada o activa, enfermedad pulmonar restrictiva crónica u obstructiva crónica incluyendo disnea en reposo por cualquier causa, disfunción incontrolada de las tiroides) que podrían causar riesgos de seguridad inaceptables o comprometer el cumplimiento con el protocolo.
    19. Pacientes con antecedentes conocidos de seropositividad frente al VIH o antecedentes de hepatitis B o C tratada/activa (no es necesaria una prueba para la selección)
    20. Mujeres embarazadas o en periodo de lactancia, o mujeres físicamente fértiles (WOCBP) que no deseen utilizar un método anticonceptivo doble durante el estudio y 3 meses después del tratamiento, uno de cuales métodos anticonceptivos deberá ser un método de barrera.
    21. Pacientes varones que no deseen utilizar un método anticonceptivo de barrera durante el estudio y durante los 3 meses después de la finalización de la evaluación del estudio.
    E.5 End points
    E.5.1Primary end point(s)
    Variable de eficacia principal:
    SLP (basado en los criterios de la EBMT modificados, es decir recaída para pacientes en RC o en RcC o PE en pacientes ni en RC ni en RcC
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Analisis correlativo de Biomarcadores
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans Information not present in EudraCT
    E.7.1.2Bioequivalence study Information not present in EudraCT
    E.7.1.3Other Information not present in EudraCT
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA82
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Ver protocolo
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months1
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 300
    F.4.2.2In the whole clinical trial 750
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Fase de seguimiento: A todos los pacientes incluidos en el estudio se les realizará un seguimiento durante todo el periodo de tratamiento o hasta la recaída/progresión y, posteriormente de la supervivencia, excepto aquellos a los que se les pierda el seguimiento. Las evaluaciones de la enfermedad se realizarán cada 3 semanas o más a menudo, si existe sospecha de progresión de la enfermedad o recaída.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2010-02-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2010-02-09
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2015-07-30
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 22:44:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA